Michael Mimouni

Dr. Michael Mimouni


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Ophthalmology
Verified
Journal Article
Closed access
Michael MimouniMichael Mimouni
Michael Mimouni
SZShiri Zayit-Soudry
Shiri Zayit-Soudry
OSOri Segal
Ori Segal
YBYoreh Barak
Yoreh Barak
ANArie Y. Nemet
Arie Y. Nemet
NGNoa Geffen
Noa Geffen

1 October 2017 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Michael MimouniMichael Mimouni
Michael Mimouni
OSOr Segev
Or Segev
DDDalia Dori
Dalia Dori
NGNoa Geffen
Noa Geffen
VFVictor Flores
Victor Flores
OSOri Segal
Ori Segal

28 July 2015 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
OSOri Segal
Ori Segal
YSYael Segal‐Trivitz
Yael Segal‐Trivitz
ANArie Y. Nemet
Arie Y. Nemet
PCPerri Cohen
Perri Cohen
NGNoa Geffen
Noa Geffen
Michael MimouniMichael Mimouni
Michael Mimouni

1 March 2018 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
PLPia Leon
Pia Leon
MPMohit Parekh
Mohit Parekh
YNYoav Nahum
Yoav Nahum
Michael MimouniMichael Mimouni
Michael Mimouni
GGGiuseppe Giannaccare
Giuseppe Giannaccare
MBMassimo Busin
Massimo Busin

15 September 2024 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
DBDaniel Bahir
Daniel Bahir
OZOmri Zur
Omri Zur
LALeah Attal
Leah Attal
ZNZaki Nujeidat
Zaki Nujeidat
AKAriela Knaanie
Ariela Knaanie
GPGilad Plopsky
Gilad Plopsky

25 September 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
YNYoav Nahum
Yoav Nahum
Michael MimouniMichael Mimouni
Michael Mimouni
ELEitan Livny
Eitan Livny
IBIrit Bahar
Irit Bahar
EHEmmilia Hodak
Emmilia Hodak
YLYael Anne Leshem
Yael Anne Leshem
Aim: To identify risk factors for the development of dupilumab-induced ocular surface disease (DIOSD) in adult patients with atopic dermatitis (AD) and describe outcomes of treatment.Methods: A retrospective institutional cohort study performed at the Rabin Medical Center, Petach Tikva, Israel. Adult patients with AD who received dupilumab from March 2018 to June 2019 were included. Demographics, AD severity scores, blood IgE levels, previous atopic keratoconjunctivitis (AKC), dermatological response to dupilumab, ophthalmological evaluation and treatment were noted. Univariate and multivariate analyses were used to identify risk factors for DIOSD.Results: Sixteen of 37 patients who were included in the study (43%) had new or exacerbated symptoms of ocular surface disease starting at 2 weeks following the first treatment. Three patients reported transient dry eye sensation which lasted 2 weeks; nine patients reported chronic dry eye sensation, and four patients (25%) had marked blepharoconjunctivitis. The presence of severe AD was the strongest predictor of DIOSD. Not a single patient with moderate AD had DIOSD. In multivariate analysis, prior AKC was a risk factor for DIOSD (R2=15.78, OR=23.28, p=0.005) while a family history of atopy was protective of DIOSD (R2=6.22, OR=0.13, p=0.05). All four patients with blepharoconjunctivitis had resolution of signs, and symptoms within days of starting periocular 0.03%–0.1% tacrolimus ointment.Conclusions: DIOSD is common in patients with AD receiving dupilumab. While most cases are mild, some patients can develop blepharoconjunctivitis which responds well to tacrolimus ointment. AD severity, and previous AKC are risk factors for DIOSD.